All Stories

  1. A systematic review on clinical adaptive radiotherapy for head and neck cancer
  2. The potential for local ablative therapy of oligometastases in head and neck squamous cell carcinoma: a real-world data analysis
  3. Personalised therapy in follicular lymphoma – is the dial turning?
  4. Career development: A balance of opportunities and choices
  5. Data from Long-term Safety of Treatment with Autologous Mesenchymal Stem Cells in Patients with Radiation-Induced Xerostomia: Primary Results of the MESRIX Phase I/II Randomized Trial
  6. Data from Long-term Safety of Treatment with Autologous Mesenchymal Stem Cells in Patients with Radiation-Induced Xerostomia: Primary Results of the MESRIX Phase I/II Randomized Trial
  7. Supplementary Data from Long-term Safety of Treatment with Autologous Mesenchymal Stem Cells in Patients with Radiation-Induced Xerostomia: Primary Results of the MESRIX Phase I/II Randomized Trial
  8. Supplementary Data from Long-term Safety of Treatment with Autologous Mesenchymal Stem Cells in Patients with Radiation-Induced Xerostomia: Primary Results of the MESRIX Phase I/II Randomized Trial
  9. Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial
  10. Cardiovascular risk factors, radiation therapy, and myocardial infarction among lymphoma survivors
  11. Patterns of relapse and long-term outcome in patients treated with a curative intent for advanced Hodgkin lymphoma
  12. Long-term Safety of Treatment with Autologous Mesenchymal Stem Cells in Patients with Radiation-Induced Xerostomia: Primary Results of the MESRIX Phase I/II Randomized Trial
  13. Intraglandular Off-the-Shelf Allogeneic Mesenchymal Stem Cell Treatment in Patients with Radiation-Induced Xerostomia: A Safety Study (MESRIX-II)
  14. Baseline FDG PET/CT in free breathing versus deep inspiration breath-hold for pediatric patients with mediastinal lymphoma
  15. Intratumor heterogeneity is biomarker specific and challenges the association with heterogeneity in multimodal functional imaging in head and neck squamous cell carcinoma
  16. Hematological toxicity in patients with solid malignant tumors treated with radiation – Temporal analysis, dose response and impact on survival
  17. Relapse localization in Danish pediatric patients with Hodgkin lymphoma
  18. Early-stage mantle cell lymphoma—a rare entity with special characteristics and needs for treatment
  19. Involved node radiation therapy in the combined modality treatment for early-stage Hodgkin lymphoma: Analysis of relapse location and long-term outcome
  20. Extranodal NK/T-cell lymphoma, nasal type, with extranasal presentation – a case report and a review of the literature
  21. ILROG emergency guidelines for radiation therapy of hematological malignancies during the COVID-19 pandemic
  22. Biological optimization for mediastinal lymphoma radiotherapy – a preliminary study
  23. Cardiac Lymphoma, a Challenging Extranodal Lymphoma
  24. Radiation dose-painting with protons vs. photons for head-and-neck cancer
  25. Incidence and survival of hypopharyngeal cancer: a Danish Nation-Wide Study from 1980 to 2014
  26. The Copenhagen Oral Cavity Squamous Cell Carcinoma database: protocol and report on establishing a comprehensive oral cavity cancer database
  27. The Optimal Use of Imaging in Radiation Therapy for Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group (ILROG)
  28. Incidence and survival of laryngeal cancer in Denmark: a nation-wide study from 1980 to 2014
  29. On the relation between improved loco-regional control and disease-free survival in head-and-neck cancer
  30. Lymphoblastic Lymphoma: Guidelines From the International Lymphoma Radiation Oncology Group (ILROG)
  31. Radiation in Central Nervous System Leukemia: Guidelines From the International Lymphoma Radiation Oncology Group
  32. MicroRNA-based classifiers for diagnosis of oral cavity squamous cell carcinoma in tissue and plasma
  33. Impact of Time to Treatment Initiation in Patients with Human Papillomavirus-positive and -negative Oropharyngeal Squamous Cell Carcinoma
  34. DAHANCA 10 – Effect of darbepoetin alfa and radiotherapy in the treatment of squamous cell carcinoma of the head and neck. A multicenter, open-label, randomized, phase 3 trial by the Danish head and neck cancer group
  35. Recommendations for the clinical management of the elderly patient with malignant lymphoma
  36. TEDDI: radiotherapy delivery in deep inspiration for pediatric patients − a NOPHO feasibility study
  37. Incidence and survival in sinonasal carcinoma: a Danish population-based, nationwide study from 1980 to 2014
  38. Metal artefact reduction for accurate tumour delineation in radiotherapy
  39. Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group
  40. Increasing incidence and survival of head and neck cancers in Denmark: a nation-wide study from 1980 to 2014
  41. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma
  42. PET/CT in Radiation Therapy Planning
  43. A failure-type specific risk prediction tool for selection of head-and-neck cancer patients for experimental treatments
  44. Synchronous, bilateral tonsillar carcinomas: Patient characteristics and human papillomavirus genotypes
  45. Incidence and survival of oropharyngeal cancer in Denmark: a nation-wide, population-based study from 1980 to 2014
  46. Life years lost attributable to late effects after radiotherapy for early stage Hodgkin lymphoma: The impact of proton therapy and/or deep inspiration breath hold
  47. Early-stage mantle cell lymphoma: a retrospective analysis from the International Lymphoma Radiation Oncology Group (ILROG)
  48. Immunohistochemical and molecular imaging biomarker signature for the prediction of failure site after chemoradiation for head and neck squamous cell carcinoma
  49. Correlation between HPV status at T and N sites of oropharyngeal squamous cell carcinomas
  50. Erratum: The role of miRNAs in human papilloma virus (HPV)-associated cancers: bridging between HPV-related head and neck cancer and cervical cancer
  51. Early Positron Emission Tomography Response–Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial
  52. Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma
  53. Increasing incidence and survival in oral cancer: a nationwide Danish study from 1980 to 2014
  54. Long-term hospitalisation rates among 5-year survivors of Hodgkin lymphoma in adolescence or young adulthood: A nationwide cohort study
  55. First-in-man mesenchymal stem cells for radiation-induced xerostomia (MESRIX): study protocol for a randomized controlled trial
  56. Construction of a pathological risk model of occult lymph node metastases for prognostication by semi-automated image analysis of tumor budding in early-stage oral squamous cell carcinoma
  57. Ultrasonic mirror image from ruthenium plaque facilitates calculation of uveal melanoma treatment dose
  58. Interobserver delineation uncertainty in involved-node radiation therapy (INRT) for early-stage Hodgkin lymphoma: on behalf of the Radiotherapy Committee of the EORTC lymphoma group
  59. Continuing rise in oropharyngeal cancer in a high HPV prevalence area: A Danish population-based study from 2011 to 2014
  60. Deep inspiration breath-hold radiotherapy for lung cancer: impact on image quality and registration uncertainty in cone beam CT image guidance
  61. Liquid fiducial marker performance during radiotherapy of locally advanced non small cell lung cancer
  62. Novel nomograms for survival and progression in HPV+ and HPV- oropharyngeal cancer: a population-based study of 1,542 consecutive patients
  63. Ionizing Radiation and High-Fat Diet: Risk for Insulin Resistance and Epigenetic Changes
  64. Feasibility of Multiparametric Imaging with PET/MR in Head and Neck Squamous Cell Carcinoma
  65. In Reply to Gunn and Garden
  66. Double positivity for HPV DNA/p16 in tonsillar and base of tongue cancer improves prognostication: Insights from a large population-based study
  67. Phase I trial of 18F-Fludeoxyglucose based radiation dose painting with concomitant cisplatin in head and neck cancer
  68. Chemotherapeutic treatment is associated with Notch1 induction in cutaneous T-cell lymphoma
  69. Editorial: Diffuse large B-cell lymphoma: survival of the fittest?
  70. Deep inspiration breath-hold volumetric modulated arc radiotherapy decreases dose to mediastinal structures in locally advanced lung cancer
  71. Elective Nodal Irradiation and Patterns of Failure in Head and Neck Cancer After Primary Radiation Therapy
  72. Geometric uncertainties in voluntary deep inspiration breath hold radiotherapy for locally advanced lung cancer
  73. Does Radiation Have a Role in Advanced Stage Hodgkin’s or Non-Hodgkin Lymphoma?
  74. Cardiovascular disease after treatment for Hodgkin's lymphoma: an analysis of nine collaborative EORTC-LYSA trials
  75. Spatio-temporal stability of pre-treatment 18F-Fludeoxyglucose uptake in head and neck squamous cell carcinomas sufficient for dose painting
  76. Staging of early lymph node metastases with the sentinel lymph node technique and predictive factors in T1/T2 oral cavity cancer: A retrospective single-center study
  77. Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
  78. Immunohistochemical biomarkers and FDG uptake on PET/CT in head and neck squamous cell carcinoma
  79. The concept and evolution of involved site radiation therapy for lymphoma
  80. Molecular profiling of tumour budding implicates TGFβ-mediated epithelial-mesenchymal transition as a therapeutic target in oral squamous cell carcinoma
  81. Increasing incidence of base of tongue cancers from 2000 to 2010 due to HPV: the largest demographic study of 210 Danish patients
  82. Minimizing Late Effects for Patients With Mediastinal Hodgkin Lymphoma: Deep Inspiration Breath-Hold, IMRT, or Both?
  83. Modern Radiation Therapy for Extranodal Lymphomas: Field and Dose Guidelines From the International Lymphoma Radiation Oncology Group
  84. Low-Dose (10-Gy) Total Skin Electron Beam Therapy for Cutaneous T-Cell Lymphoma: An Open Clinical Study and Pooled Data Analysis
  85. Modern Radiation Therapy for Primary Cutaneous Lymphomas: Field and Dose Guidelines From the International Lymphoma Radiation Oncology Group
  86. Radiation Therapy Planning for Early-Stage Hodgkin Lymphoma: Experience of the International Lymphoma Radiation Oncology Group
  87. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial
  88. Reproducibility of18F-FDG PET uptake measurements in head and neck squamous cell carcinoma on both PET/CT and PET/MR
  89. A new method to estimate doses to the normal tissues after past extended and involved field radiotherapy for Hodgkin lymphoma
  90. Prognostic Factors
  91. H odgkin's Disease
  92. A Decade of Comparative Dose Planning Studies for Early-Stage Hodgkin Lymphoma: What Can We Learn?
  93. Human Papillomavirus in Head and Neck Squamous Cell Carcinoma of Unknown Primary Is a Common Event and a Strong Predictor of Survival
  94. The EXTREME regimen for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): Treatment outcome in a single institution cohort
  95. Comment on: “Clinical Features, Management, and Prognosis of an International Series of 161 Patients With Limited-Stage Diffuse Large B-Cell Lymphoma of the Bone (the IELSG-14 Study)”
  96. A high and increasing HPV prevalence in tonsillar cancers in Eastern Denmark, 2000-2010: The largest registry-based study to date
  97. In Vivo Treatment Sensitivity Testing With Positron Emission Tomography/Computed Tomography After One Cycle of Chemotherapy for Hodgkin Lymphoma
  98. Follicular lymphoma of the ocular adnexal region: A nation-based study
  99. Geometric distortions of diffusion weighted imaging of the head/neck in combined PET/MR: optimization of image acquisition and post-processing correction for oncology applications
  100. Prognostic value of 18F-fludeoxyglucose uptake in 287 patients with head and neck squamous cell carcinoma
  101. Prospective phase II trial of image-guided radiotherapy in Hodgkin lymphoma: Benefit of deep inspiration breath-hold
  102. Modern Radiation Therapy for Hodgkin Lymphoma: Field and Dose Guidelines From the International Lymphoma Radiation Oncology Group (ILROG)
  103. Prescribing and evaluating target dose in dose-painting treatment plans
  104. Cardiovascular disease after cancer therapy
  105. Recurrences after intensity modulated radiotherapy for head and neck squamous cell carcinoma more likely to originate from regions with high baseline [18F]-FDG uptake
  106. Modern Radiation Therapy for Nodal Non-Hodgkin Lymphoma—Target Definition and Dose Guidelines From the International Lymphoma Radiation Oncology Group
  107. MiR-21 Expression in the Tumor Stroma of Oral Squamous Cell Carcinoma: An Independent Biomarker of Disease Free Survival
  108. Radiotherapy for indolent lymphomas: how much is enough?
  109. Mesenchymal stem cell therapy for salivary gland dysfunction and xerostomia: a systematic review of preclinical studies
  110. Doses to head and neck normal tissues for early stage Hodgkin lymphoma after involved node radiotherapy
  111. Edited by AnasYounes and BertrandCoiffier (Eds.) Lymphoma. Diagnosis and Treatment. Humana Press, New York, 2013, 411 pages.
  112. Interactive Decision-Support Tool for Risk-Based Radiation Therapy Plan Comparison for Hodgkin Lymphoma
  113. Heart, Coronary Arteries, Aorta and Great Vessels, Arteries and Veins, Microcirculation
  114. Optimizing the radiation therapy dose prescription for pediatric medulloblastoma: Minimizing the life years lost attributable to failure to control the disease and late complication risk
  115. The impact of involved node, involved field and mantle field radiotherapy on estimated radiation doses and risk of late effects for pediatric patients with Hodgkin lymphoma
  116. Human papillomavirus and oropharyngeal cancer in Greenland in 1994–2010
  117. Three-year follow-up of sentinel node-negative patients with early oral cavity squamous cell carcinoma
  118. Lena Specht
  119. Doses to Carotid Arteries After Modern Radiation Therapy for Hodgkin Lymphoma: Is Stroke Still a Late Effect of Treatment?
  120. Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
  121. The effect on esophagus after different radiotherapy techniques for early stage Hodgkin's lymphoma
  122. Deep inspiration breath hold radiotherapy for locally advanced lung cancer: Comparison of different treatment techniques on target coverage, lung dose and treatment delivery time
  123. Factors associated with acute and late dysphagia in the DAHANCA 6 & 7 randomized trial with accelerated radiotherapy for head and neck cancer
  124. Stability of percutaneously implanted markers for lung stereotactic radiotherapy
  125. Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma
  126. Ten-year retrospective study of head and neck carcinoma in situ: incidence, treatment, and clinical outcome
  127. T-Cell Lymphomas FrancineFoss (ed.) Humana Press, New York, 2013, 340 pages.
  128. Three-dimensional MRI-linac intra-fraction guidance using multiple orthogonal cine-MRI planes
  129. OP182
  130. Long-term outcome for gastric marginal zone lymphoma treated with radiotherapy: a retrospective, multi-centre, International Extranodal Lymphoma Study Group study
  131. Involved Node Radiation Therapy: An Effective Alternative in Early-Stage Hodgkin Lymphoma
  132. Interim positron emission tomography in early stage Hodgkin lymphoma: is there evidence for its prognostic and predictive value in patients treated with standard combined modality treatment?
  133. Percutaneously implanted markers in peripheral lung tumours: Report of complications
  134. Evaluation of methods for selecting the midventilation bin in 4DCT scans of lung cancer patients
  135. Failure-probability driven dose painting
  136. Differences in Radiotherapy Delivery and Outcome Due to Contouring Variation
  137. Routine Bone Marrow Biopsy Has Little or No Therapeutic Consequence for Positron Emission Tomography/Computed Tomography–Staged Treatment-Naive Patients With Hodgkin Lymphoma
  138. Interobserver delineation variation in lung tumour stereotactic body radiotherapy
  139. Risk of Developing Cardiovascular Disease After Involved Node Radiotherapy Versus Mantle Field for Hodgkin Lymphoma
  140. Radiotherapy Studies and Extra-nodal Non-Hodgkin Lymphomas, Progress and Challenges
  141. Methods for estimating the site of origin of locoregional recurrence in head and neck squamous cell carcinoma
  142. Life years lost-comparing potentially fatal late complications after radiotherapy for pediatric medulloblastoma on a common scale
  143. The role of miRNAs in human papilloma virus (HPV)-associated cancers: bridging between HPV-related head and neck cancer and cervical cancer
  144. Prevalence and peak incidence of acute and late normal tissue morbidity in the DAHANCA 6&7 randomised trial with accelerated radiotherapy for head and neck cancer
  145. Low-dose total skin electron beam therapy as a debulking agent for cutaneous T-cell lymphoma: an open-label prospective phase II study
  146. Positron emission tomography/computed tomography surveillance in patients with Hodgkin lymphoma in first remission has a low positive predictive value and high costs
  147. Artifacts in Conventional Computed Tomography (CT) and Free Breathing Four-Dimensional CT Induce Uncertainty in Gross Tumor Volume Determination
  148. Evaluation of dose to cardiac structures during breast irradiation
  149. Does transfusion improve the outcome for HNSCC patients treated with radiotherapy? – Results from the randomized DAHANCA 5 and 7 trials
  150. Total skin electron beam therapy for cutaneous T-cell lymphoma: A nationwide cohort study from Denmark
  151. The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer: Evaluation of the randomised DAHANCA 6&7 trial
  152. Does hyperbaric oxygen treatment have the potential to increase salivary flow rate and reduce xerostomia in previously irradiated head and neck cancer patients? A pilot study
  153. Risk factors for radiation-induced hypothyroidism
  154. Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphoma
  155. Different miRNA signatures of oral and pharyngeal squamous cell carcinomas: a prospective translational study
  156. The prevalence of occult metastases in nonsentinel lymph nodes after step-serial sectioning and immunohistochemistry in cN0 oral squamous cell carcinoma
  157. Radiotherapy for Hodgkin Lymphoma
  158. Methodologies for localizing loco-regional hypopharyngeal carcinoma recurrences in relation to FDG-PET positive and clinical radiation therapy target volumes
  159. Survival of head and neck cancer in Greenland
  160. Proton Therapy for Hodgkin Lymphoma
  161. Future Prospects for Radiotherapy for Hodgkin Lymphoma
  162. History of Radiotherapy of Hodgkin’s Disease (Now Hodgkin Lymphoma)
  163. Evaluation of Response After Radiotherapy for Hodgkin Lymphoma
  164. Traditional and Modern Techniques for Radiation Treatment Planning
  165. Background and Rationale for Radiotherapy in Early-Stage Hodgkin Lymphoma
  166. Target Definitions for Hodgkin Lymphoma: The Involved Node Radiation Field Concept
  167. Prognostic Factors
  168. Staging systems and staging investigations at presentation
  169. Deviations in delineated GTV caused by artefacts in 4DCT
  170. Chemotherapy alone vs. radiotherapy alone vs. chemotherapy plus radiotherapy in the primary treatment of localised non-Hodgkin's lymphoma
  171. Erosive potential of saliva stimulating tablets with and without fluoride in irradiated head and neck cancer patients
  172. Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin's lymphoma: a systematic review
  173. Improved prognosis for localized malignant lymphomas of the head and neck
  174. The effect of different lung densities on the accuracy of various radiotherapy dose calculation methods: Implications for tumour coverage
  175. Hodgkin's disease and age*
  176. Hodgkin's disease: Recent concepts in classification and treatment
  177. Therapeutic implications of mediastinal involvement in advanced Hodgkin's disease
  178. Prognostic factors in Hodgkin's disease stage III with special reference to tumour burden
  179. Prognostic factors in Hodgkin's disease stage IV
  180. Prognostic significance of tumour burden in Hodgkin's disease PS I and II
  181. Testicular function in young men in long-term remission after treatment for the early stages of Hodgkin's disease
  182. Antibody response to pneumococcal vaccine in patients with early stage Hodgkin's disease
  183. Ovarian function in young women in long-term remission after treatment for Hodgkin's disease stage I or II
  184. The conundrum of hodgkin lymphoma nodes: To be or not to be included in the involved node radiation fields. The EORTC-GELA lymphoma group guidelines
  185. A Prospective, Open-Label Study of Low-Dose Total Skin Electron Beam Therapy in Mycosis Fungoides
  186. PET/CT in the management of haematological malignancies
  187. Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin Lymphoma
  188. Need for Intensive Histopathologic Analysis to Determine Lymph Node Metastases When Using Sentinel Node Biopsy in Oral Cancer
  189. The nimorazole regimen in patients with head and neck cancer can increase the effect of vitamin K antagonists
  190. The role of image guidance in respiratory gated radiotherapy
  191. Papillary microcarcinoma of the thyroid gland: Is the immunohistochemical expression of cyclin D1 or galectin-3 in primary tumour an indicator of metastatic disease?
  192. Interfractional changes in tumour volume and position during entire radiotherapy courses for lung cancer with respiratory gating and image guidance
  193. Can audio coached 4D CT emulate free breathing during the treatment course?
  194. FDG-PET scan and treatment planning for early stage Hodgkin lymphoma
  195. Do We Need an Early Unfavorable (Intermediate) Stage of Hodgkin's Lymphoma?
  196. Phase I/II clinical and pharmacokinetic study evaluating a fully human monoclonal antibody against EGFr (HuMax-EGFr) in patients with advanced squamous cell carcinoma of the head and neck
  197. Early Interim 2-[18F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Is Prognostically Superior to International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: A Report From a Joint Italian-Danish Study
  198. 2-[18F]Fluoro-2-Deoxyglucose Positron-Emission Tomography in Staging, Response Evaluation, and Treatment Planning of Lymphomas
  199. Intra- and interfraction breathing variations during curative radiotherapy for lung cancer
  200. Clinical impact of FDG-PET/CT in the planning of radiotherapy for early-stage Hodgkin lymphoma
  201. PET/CT in head and neck cancer
  202. Revised Response Criteria for Malignant Lymphoma
  203. Nasopharyngeal carcinoma. Treatment planning with IMRT and 3D conformal radiotherapy
  204. Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials
  205. Cardiac and pulmonary complication probabilities for breast cancer patients after routine end-inspiration gated radiotherapy
  206. Reduction of cardiac and pulmonary complication probabilities after breathing adapted radiotherapy for breast cancer
  207. Hodgkin Lymphoma
  208. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: Concepts and guidelines
  209. Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptake
  210. The role of SPECT-CT in the lymphoscintigraphic identification of sentinel nodes in patients with oral cancer
  211. The Danish national guidelines for treatment of oral squamous cell carcinoma
  212. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma
  213. Chemotherapy, radiotherapy and combined modality for Hodgkin's disease, with emphasis on second cancer risk
  214. Breathing adapted radiotherapy for breast cancer: Comparison of free breathing gating with the breath-hold technique
  215. Report from the Rockefellar Foundation Sponsored International Workshop on reducing mortality and improving quality of life in long-term survivors of Hodgkin's disease: July 9-16, 2003, Bellagio, Italy
  216. Nimorazole may increase the effect of phenprocoumon
  217. FDG-PET in the clinical management of Hodgkin lymphoma
  218. Consolidation radiotherapy may improve outcomes in people with Hodgkin's disease achieving complete remission after combination chemotherapy
  219. Breathing adapted radiotherapy of breast cancer: reduction of cardiac and pulmonary doses using voluntary inspiration breath-hold
  220. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6&7 randomised controlled trial
  221. In response to Dr. Remouchamps
  222. Chemotherapy alone vs. radiotherapy alone vs. chemotherapy plus radiotherapy in the primary treatment of localised non-Hodgkin's lymphoma
  223. Phase II study of palliative low-dose local radiotherapy in disseminated indolent non-Hodgkin’s lymphoma and chronic lymphocytic leukemia
  224. Oral complications in the head and neck radiation patient
  225. Serum Lactate Dehydrogenase Isoenzyme 1 in Patients with Seminoma Stage I Followed with Surveillance
  226. Osteoradionecrosis of the jaws: Clinical characteristics and relation to the field of irradiation
  227. Phase II study of docetaxel and cisplatin in patients with recurrent or disseminated squamous-cell carcinoma of the head and neck
  228. PROGNOSTIC FACTORS FOR RELAPSE IN STAGE I SEMINOMA MANAGED BY SURVEILLANCE
  229. A Prognostic Score for Advanced Hodgkin's Disease
  230. Transitory blindness after retrobulbar irradiation of Graves' ophthalmopathy
  231. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85
  232. Survival analysis of patients with clinical stages I or II Hodgkin's disease who have relapsed after initial treatment with radiotherapy alone
  233. Prognostic factors in Hodgkin's disease
  234. Salvage of relapse of patients with Hodgkin's disease in clinical stages I or II who were staged with laparotomy and initially treated with radiotherapy alone. A report from the International Database on Hodgkin's disease
  235. Surveillance following orchidectomy for stage I seminoma of the testis
  236. The integration of radiotherapy into the primary treatment of non-Hodgkin's lymphoma
  237. Tumour burden as the main indicator of prognosis in Hodgkin's disease
  238. Prognostic factors in Hodgkin's disease
  239. Tumor cell concentration and tumor burden in relation to histopathologic subtype and other prognostic factors in early stage Hodgkin's disease
  240. Tumor burden as the most important prognostic factor in early stage Hodgkin's disease.Relations to other prognostic factors and implications for choice of treatment
  241. RISK OF THERAPY-RELATED LEUKAEMIA AND PRELEUKAEMIA AFTER HODGKIN'S DISEASE
  242. Tumour burden in early stage Hodgkin's disease: the single most important prognostic factor for outcome after radiotherapy